全文获取类型
收费全文 | 6811篇 |
免费 | 458篇 |
国内免费 | 51篇 |
专业分类
耳鼻咽喉 | 68篇 |
儿科学 | 119篇 |
妇产科学 | 107篇 |
基础医学 | 876篇 |
口腔科学 | 55篇 |
临床医学 | 751篇 |
内科学 | 1841篇 |
皮肤病学 | 94篇 |
神经病学 | 677篇 |
特种医学 | 243篇 |
外科学 | 942篇 |
综合类 | 49篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 379篇 |
眼科学 | 103篇 |
药学 | 439篇 |
中国医学 | 2篇 |
肿瘤学 | 573篇 |
出版年
2023年 | 38篇 |
2022年 | 55篇 |
2021年 | 143篇 |
2020年 | 97篇 |
2019年 | 142篇 |
2018年 | 188篇 |
2017年 | 122篇 |
2016年 | 137篇 |
2015年 | 174篇 |
2014年 | 226篇 |
2013年 | 316篇 |
2012年 | 535篇 |
2011年 | 516篇 |
2010年 | 314篇 |
2009年 | 296篇 |
2008年 | 463篇 |
2007年 | 503篇 |
2006年 | 414篇 |
2005年 | 463篇 |
2004年 | 475篇 |
2003年 | 396篇 |
2002年 | 370篇 |
2001年 | 65篇 |
2000年 | 57篇 |
1999年 | 52篇 |
1998年 | 83篇 |
1997年 | 69篇 |
1996年 | 54篇 |
1995年 | 60篇 |
1994年 | 52篇 |
1993年 | 39篇 |
1992年 | 44篇 |
1991年 | 35篇 |
1990年 | 21篇 |
1989年 | 27篇 |
1988年 | 18篇 |
1987年 | 21篇 |
1986年 | 18篇 |
1985年 | 19篇 |
1984年 | 15篇 |
1983年 | 15篇 |
1982年 | 10篇 |
1980年 | 15篇 |
1978年 | 12篇 |
1977年 | 14篇 |
1974年 | 13篇 |
1973年 | 12篇 |
1972年 | 9篇 |
1971年 | 14篇 |
1967年 | 8篇 |
排序方式: 共有7320条查询结果,搜索用时 31 毫秒
101.
102.
Andr��a Chabot-Naud George Rakovich Karine Chagnon Denise Ouellette Gilles Beauchamp 《Canadian respiratory journal》2011,18(2):79-80
A case of azygos lobe is presented. An azygos lobe is an accessory lobe of the lung that may occasionally be confused with a pathological process such as a bulla, lung abscess or neoplasm. Its pathogenesis is discussed, as are the characteristic x-ray features that enable an accurate diagnosis. 相似文献
103.
104.
105.
Mathieu Wurtz Elisa Ruhland XuanLi Liu Izzie-Jacques Namer Viola Mazzoleni Dan Lipsker Daniel Keller Gilles Prvost David Gaucher 《Investigative ophthalmology & visual science》2021,62(1)
PurposeEndophthalmitis models have reported the virulent role of Panton-Valentine leucocidin (PVL) secreted by Staphylococcus aureus on the retina. PVL targets retinal ganglion cells (RGCs), expressing PVL membrane receptor C5aR. Interactions between PVL and retinal cells lead to glial activation, retinal inflammation, and apoptosis. In this study, we explored oxidative stress and retinal neurotransmitters in a rabbit retinal explant model incubated with PVL.MethodsReactive oxygen species (ROS) production in RGCs has been assessed with fluorescent probes and immunohistochemistry. Nuclear magnetic resonance (NMR) spectroscopy quantified retinal concentrations of antioxidant molecules and neurotransmitters, and concentrations of neurotransmitters released in the culture medium. Quantifying the expression of some pro-inflammatory and anti-inflammatory factors was performed using RT-qPCR.ResultsPVL induced a mitochondrial ROS production in RGCs after four hours’ incubation with the toxin. Enzymatic sources of ROS, involving nicotinamide adenine dinucleotide phosphate–oxidase and xanthine oxidase, were also activated after four hours in PVL-treated retinal explants. Retinal antioxidants defenses, that is, glutathione, ascorbate and taurine, decreased after two hours’ incubation with PVL. Glutamate retinal concentrations and glutamate release in the culture medium remained unaltered in PVL-treated retinas. GABA, glycine, and acetylcholine (Ach) retinal concentrations decreased after PVL treatment. Glycine release in the culture medium decreased, whereas Ach release increased after PVL treatment. Expression of proinflammatory and anti-inflammatory cytokines remained unchanged in PVL-treated explants.ConclusionsPVL activates oxidative pathways and alters neurotransmitter retinal concentrations and release, supporting the hypothesis that PVL could induce a neurogenic inflammation in the retina. 相似文献
106.
107.
108.
109.
110.
Wolfgang Schoels MD David Steinhaus MD W. Ben Johnson MD Gilles OHara MD Joerg O. Schwab MD Inge Jenniskens MSc Paul J. DeGroot MS Feng Tang PhD Erhard Helmling MD EnTrust Clinical Study Investigators 《Heart rhythm》2007,4(7):879-885
BACKGROUND: Previous studies in implantable cardioverter-defibrillator (ICD) patients demonstrated the efficacy and safety of antitachycardia pacing (ATP) for rapid ventricular tachycardias (VT). To prevent shock delay in case of ATP failure, a new feature (ATP during charging) was developed to deliver ATP for rapid VT while charging for shock. OBJECTIVE: The purpose of this study was to determine the efficacy and safety of this new feature. METHODS: In a prospective, nonrandomized trial, patients with standard ICD indication received an EnTrust ICD. VT and ventricular fibrillation (VF) episodes were reviewed for appropriate detection, ATP success, rhythm acceleration, and related symptoms. RESULTS: In 421 implanted patients, 116 VF episodes occurred in 37 patients. Eighty-four (72%) episodes received ATP during or before charging. ATP prevented a shock in 58 (69%) of 84 episodes in 15 patients. ATP stopped significantly more monomorphic (77%) than polymorphic VTs (44%, P = .05). Five (6%) episodes accelerated after ATP but were terminated by the backup shock(s). No symptoms were related to ATP during charging. In four patients, 38 charges were saved by delivering ATP before charging. Of 98 induced VF episodes, 28% were successfully terminated by ATP versus 69% for spontaneous episodes (P <.01). CONCLUSION: Most VTs detected in the VF zone can be painlessly terminated by ATP delivered during charging, with a low risk of acceleration or symptoms. ATP before charging allows delivery of two ATP attempts before shock in the same time that would otherwise be required to deliver only one ATP plus a shock. It also offers potential battery energy savings. 相似文献